In September 2026, the University of Melbourne joined the Structural Genomics Consortium, becoming Australasia's first affiliated site in a global effort to map pharmacological tools for every human protein by 2035. The initiative, called Target 2035, wagers that artificial intelligence — trained on vast, openly shared experimental data — can transform drug discovery from costly guesswork into informed prediction. At its heart, the endeavor is a quiet revolution in how humanity organizes the search for healing: away from proprietary isolation and toward coordinated, collective knowledge.
Melbourne Joins Global Drug Discovery Consortium to Accelerate AI-Driven Medicine Development
The initiative addresses rare diseases affecting approximately 1 in 12 people globally, with potential to develop treatments for patients currently lacking therapeutic options.
Finding the right matches is an enormous scientific challenge.
Mark
So the University of Melbourne is joining this consortium. What exactly are they committing to do?
Mimi
They're establishing a lab—SGC-Melbourne—that will generate data on how molecules interact with proteins. That data gets shared openly with a global network so AI systems can learn from it.
Luke
But who's paying for this? Is this a University of Melbourne initiative, or is the SGC funding it?
Mimi
The source says the SGC will provide access to technologies and infrastructure, but it doesn't specify the funding model or who bears the operating costs.
Mark
Why does this matter? Why not just have one central lab doing this work?
Mimi
Because you need scale and diversity. Different labs have different expertise. Melbourne brings protein science and structural biology expertise. Having distributed labs means you generate data faster and in different contexts.
Luke
The source mentions "complementary scientific strengths." That's vague. What specifically does Melbourne bring that, say, a lab in Europe doesn't already have?
Mimi
The Dean mentions mitochondrial biology, fertility and developmental biology, immunology, infectious disease, and cancer research. Those are the areas where Melbourne's existing strength sits.
Mark
And the rare disease angle—is that unique to Melbourne, or is that a global priority for the whole consortium?
Mimi
It's a global priority, but Melbourne is positioned to focus on it because of the partnerships with institutions like Murdoch Children's Research Institute.
Luke
The source says rare diseases affect "one in 12 people globally." That's a staggering number. But it also says "each rare disease affects fewer than one in 2000 people." Those two facts sit in tension—how do you reconcile them?
Mimi
You don't, really. There are thousands of rare diseases, each individually uncommon, but collectively they touch a huge population. The point is that no single disease is commercially attractive to pharma, but the aggregate problem is enormous.
Mark
So what happens next? When does SGC-Melbourne actually start generating data?
Mimi
The source doesn't say. It announces the establishment, but not a timeline for operations or first results.
Il Polso
- Drug discovery is bottlenecked not by ambition but by data — the high-quality experimental datasets needed to train AI models simply do not yet exist at the scale required.
- More than 6,000 rare diseases collectively affect one in twelve people globally, yet pharmaceutical companies have little financial incentive to pursue treatments for small patient populations.
- SGC-Melbourne, led by Professor Megan Maher, will generate protein-compound interaction data locally — eliminating the cost and delay of shipping samples overseas — and feed it into a freely shared global pool.
- The hub will collaborate with major Melbourne biomedical institutions, including the Walter and Eliza Hall Institute and Peter MacCallum Cancer Centre, pooling capabilities available in only a handful of centers worldwide.
- Australia's recent entry into Horizon Europe amplifies the significance of this moment, positioning the country as an active node in an increasingly interconnected international scientific network.
In September 2026, the University of Melbourne joined the Structural Genomics Consortium, becoming Australasia's first affiliated site in a global effort to map pharmacological tools for every human protein by 2035. The initiative, called Target 2035, wagers that artificial intelligence — trained on vast, openly shared experimental data — can transform drug discovery from costly guesswork into informed prediction. At its heart, the endeavor is a quiet revolution in how humanity organizes the search for healing: away from proprietary isolation and toward coordinated, collective knowledge.
In September 2026, the University of Melbourne established SGC-Melbourne, becoming Australasia's first site within the Structural Genomics Consortium — a global academic and industry network pursuing one of modern medicine's most audacious goals: a pharmacological tool for every human protein by 2035.
The challenge the initiative addresses is structural. Most medicines work by binding to proteins, but with thousands of human proteins and billions of possible compounds, finding the right matches has historically been slow and expensive. Artificial intelligence could change this — machine-learning models trained on molecular interaction data might predict promising compounds before a single experiment is run. The missing ingredient is data, and SGC-Melbourne exists to help generate it.
Led by Professor Megan Maher, the site will produce protein-compound interaction data under shared Target 2035 standards and make it openly available to the global network. The University of Melbourne brings considerable assets: it sits within Australasia's largest biomedical precinct and will collaborate with the Walter and Eliza Hall Institute, Peter MacCallum Cancer Centre, and Murdoch Children's Research Institute. Crucially, all work can be done locally, reducing cost and delay.
The initiative carries particular urgency for rare diseases. Over 6,000 known rare disorders affect roughly one in twelve people worldwide, yet pharmaceutical companies have little incentive to develop treatments for small patient populations. Researcher Professor David Thorburn notes that many of these diseases remain poorly understood at the molecular level — patients carry mutations affecting specific proteins, but scientists often don't know what those proteins do or how to intervene. SGC-Melbourne aims to change that, characterizing these proteins and identifying compounds that interact with them.
What distinguishes Target 2035 is its commitment to openness. All data generated will be shared freely, building a global commons for drug discovery. For patients lacking treatment options, and for a scientific community long accustomed to proprietary secrecy, SGC-Melbourne signals a meaningful shift — from isolated effort to coordinated global work, from trial and error to informed prediction.
The University of Melbourne has joined one of the world's most ambitious efforts to remake how medicines are discovered. In September 2026, the institution established SGC-Melbourne, becoming Australasia's first affiliated site of the Structural Genomics Consortium, a global network of academic and industry laboratories working toward a singular goal: creating a pharmacological tool for every human protein by 2035.
The mission, called Target 2035, rests on a fundamental problem in drug discovery. Most medicines work by binding to proteins—imagine a key fitting into a molecular lock—but with thousands of human proteins and billions of possible compounds, finding the right matches has always been a matter of trial and error, expensive and slow. The consortium is betting that artificial intelligence can change this. Machine-learning models, trained on vast datasets of how molecules interact with proteins, could predict which compounds are most likely to work before a single experiment is run. The bottleneck, however, is data. The high-quality, consistently generated experimental datasets needed to train these AI systems simply do not exist at the scale required. SGC-Melbourne will help build them.
Led by Professor Megan Maher, an internationally recognized chemist, the new site will generate protein-compound interaction data and make it openly available to the global network. This is not a closed laboratory hoarding proprietary findings. The entire point is to feed a shared pool of knowledge that AI systems can learn from. The University of Melbourne brings significant assets to this work: it sits within Australasia's largest biomedical precinct and will collaborate with partner institutions including the Walter and Eliza Hall Institute, Peter MacCallum Cancer Centre, and Murdoch Children's Research Institute. Together, they will produce proteins, study them, and screen them using shared Target 2035 standards, all without shipping samples overseas—a practical advantage that reduces both cost and delay.
The work carries particular weight for rare diseases. More than 6,000 known rare disorders exist, collectively affecting roughly one in twelve people globally, yet pharmaceutical companies have little incentive to develop treatments for conditions affecting small patient populations. Professor David Thorburn, a researcher at Murdoch Children's Research Institute, frames the opportunity plainly: many rare diseases remain poorly understood at the molecular level. Patients carry genetic mutations that affect specific proteins, but scientists often do not know what those proteins actually do or how to intervene. By characterizing these proteins and identifying compounds that interact with them, SGC-Melbourne can help unlock the biology of disease, reducing the risk of early-stage research and moving patients closer to treatments they currently lack.
The consortium will provide SGC-Melbourne with access to specialized technologies, screening libraries, and data infrastructure developed across its international network—capabilities available in only a handful of centers worldwide. This is not a small advantage. The University of Melbourne's Dean of Science, Professor Moira O'Bryan, described the establishment of SGC-Melbourne as a vote of confidence in Australian science. It also positions Australia to benefit from its recent decision to join Horizon Europe, strengthening connections between Australian researchers and international scientific networks.
What makes Target 2035 distinctive is its commitment to openness. The data generated will be shared freely, creating a global commons for drug discovery. The long-term vision is to make the search for new medicines increasingly computational, replacing much of the experimental guesswork with prediction. For patients with rare diseases, for researchers working on proteins that have so far resisted study, and for the broader project of accelerating medicine development, SGC-Melbourne represents a shift in how discovery happens—from isolated effort to coordinated global work, from proprietary secrecy to shared knowledge, from trial and error to informed prediction.
Citazioni salienti
With thousands of human proteins and billions of possible compounds, finding the right matches is an enormous scientific challenge.— Professor Megan Maher, SGC-Melbourne Chief Scientist
Although each rare disease affects fewer than one in 2000 people, there are more than 6,000 known rare disorders that collectively affect around one in 12 people.— Professor David Thorburn, Murdoch Children's Research Institute
Vuoi la storia completa?
Leggi l'originale su Mirage News ↗
Technology